Chen Xiang, Zhang Kun, Hock Janet, Wang Chunyu, Yu Xijie
Laboratory of Endocrinology and Metabolism, Department of Endocrinology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University , Chengdu, China.
The Polis Center, Indiana University-Purdue University Indianapolis , Indianapolis, IN, USA.
Bone Res. 2016 Nov 29;4:16035. doi: 10.1038/boneres.2016.35. eCollection 2016.
Type II autosomal dominant osteopetrosis (ADO2), which is the most common form of osteopetrosis, is caused by heterozygous mutations in the chloride channel 7 () gene. The osteopetrosis of ADO2 has been attributed to hypofunctional osteoclasts. The mechanism underlying the abnormality in osteoclast function remains largely unknown. This study was designed to investigate gene mutations and osteoclast function in a case that was clinically diagnosed as ADO2. Genomic DNA was extracted from blood samples of this patient, and the 25 exons of were amplified. Peripheral blood from the ADO2 subject and a healthy age- and sex-matched control was used to evaluate osteoclastogenesis, osteoclast morphology, and bone resorption. Analysis of DNA from the patient showed a germline heterozygous missense mutation, c.1856C>T (p.P619L), in exon 20 of . A similar homozygous mutation at this site was previously reported in a patient with autosomal recessive osteopetrosis. When cultured, the peripheral blood mononuclear cells (PBMCs) from the ADO2 patient spontaneously differentiated into mature osteoclasts . The ADO2 patient's PBMCs formed enhanced, but heterogeneous, osteoclasts in both the presence and absence of macrophage-colony stimulating factor, and nuclear factor-ĸB ligand. Bone resorption was reduced in the ADO2 patient's osteoclasts, which exhibited aberrant morphology and abnormal distribution of integrin aβ. Gene analysis found increased expression and reduced and expression in ADO2 cells. In conclusion, our data suggest that enhanced, heterogeneous osteoclast induction may be an intrinsic characteristic of ADO2.
II型常染色体显性遗传性骨硬化症(ADO2)是最常见的骨硬化症形式,由氯离子通道7(CLCN7)基因的杂合突变引起。ADO2型骨硬化症归因于破骨细胞功能减退。破骨细胞功能异常的潜在机制在很大程度上仍然未知。本研究旨在调查一例临床诊断为ADO2的病例中的基因突变和破骨细胞功能。从该患者的血液样本中提取基因组DNA,并扩增CLCN7的25个外显子。使用来自ADO2受试者以及年龄和性别匹配的健康对照的外周血来评估破骨细胞生成、破骨细胞形态和骨吸收。对患者DNA的分析显示,CLCN7第20外显子存在种系杂合错义突变,c.1856C>T(p.P619L)。此前在一名常染色体隐性遗传性骨硬化症患者中报道过该位点类似的纯合突变。培养时,ADO2患者的外周血单核细胞(PBMC)自发分化为成熟破骨细胞。在存在和不存在巨噬细胞集落刺激因子以及核因子-κB配体的情况下,ADO2患者的PBMC均形成增强但异质性的破骨细胞。ADO2患者破骨细胞的骨吸收减少,其表现出异常形态和整合素αβ的异常分布。基因分析发现,ADO2细胞中CLCN7表达增加,而TCIRG1和OSTM1表达减少。总之,我们的数据表明,增强的、异质性破骨细胞诱导可能是ADO2的一个内在特征。